Invitrogen™ T-bet Monoclonal Antibody (eBio39D (39D, 3-9D)), eBioscience™

Description

Description: The eBio39D monoclonal antibody reacts with mouse, rat and human T-bet. T-bet is a Th1-specific T-box transcription factor critical to the development of the Th1 CD4+ T cell lineage. This is known based on the observations that T-Bet deficient mice have impaired Th1 cell development, and that ectopic expression of T-Bet results in development skewed to the Th1 lineage. T-Bet expression is induced by the Th1 cytokine IFN-gamma, and T-Bet also regulates the expression of IFN-gamma, likely, at least in part, through the modification of DNA accessibility and histone remodeling. In addition to IFN-gamma, T-Bet is also known to regulate the expression of IL-12Rbeta and IL-2. Moreover, T-Bet plays a role in class-switch recombination in B-cells. Applications Reported: This eBio39D (39D, 3-9D) antibody has been reported for use in immunoprecipitation, and immunoblotting (WB). Applications Tested: This eBio39D (39D, 3-9D) antibody has been tested by western blot analysis of Th1-polarized mouse CD4+ T cells and can be used at 2 μg/mL as a starting dilution for western blotting. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

T-bet, also known as TBX21, is a T-cell specific transcription factor containing a single T-box DNA-binding domain. It controls the expression of the TH1 cytokine, interferon-gamma. Both Th1 and Th17 cells are crucial in immune regulation and autoimmune disease development. T-bet initiates Th1 lineage development from naive Th precursor cells and directs T cell differentiation to Th1 versus Th17. T-bet is cooperating with Stat4 (signal tranducer and activator of transcription 4) in programming chromatin architecture for Th1 gene expression. Genetic variations in T-bet are associated with susceptibility to aspirin-induced asthma and nasal polyps.